US › Healthcare

InMed Pharmaceuticals Inc (INM)

US · Healthcare · Drug Manufacturers - Specialty & Generic

$1.39+8.59%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$2.06B

Revenue YoY

+115691.6%

Net profit

$539.7M

EPS

$-0.73

Net margin

26.2%

Key statistics

Market cap

$7.2M

Forward P/E

0.0

P/B

1.01

Book value

$2.08

EPS (TTM)

$-1.47

52-week high

$2.50

52-week low

$0.57

50-day MA

$1.51

200-day MA

$1.18

Beta

0.98

Analyst view

with an average price target of $20.00.

Shareholding

Insiders

0.12%

Institutions

84.66%

Largest institutional holders

Fund	Stake
Vivo Capital, LLC	14.95%
Squadron Capital Management LLC	6.09%
Sabby Management LLC	4.13%
Citadel Advisors Llc	0.88%
SEVEN GRAND MANAGERS, LLC	0.47%
Virtu Financial LLC	0.37%
TWO SIGMA SECURITIES, LLC	0.35%
Stratos Wealth Partners, LTD	0.20%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for InMed Pharmaceuticals Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.